Overall, we noted that anti-PD/PD-L1 drugs increased tumor response (RR 1.91, 95% CI 1.62-2.26, P < 0.001; Figure S3) and reduced the risk of death significantly (HR 0.72, 95% CI 0.66-0.78, P < 0.001; Figure 1), irrespective of tumor type, compared with the control treatment. The gene discussed is CD274; the disease is neoplasm.